Elevate your protein production game with SynWeave™—the innovative platform designed to improve manufacturability and boost productivity. Join us for an exclusive webinar featuring Sunit Maity, PhD, AVP – Biologics Services at Syngene International Ltd. and discover how our advanced technology and process development expertise can drive your success.
Topics Covered
- The science and history behind SynWeave™
- How to accelerate cell line development by up to 10 weeks and boost yields up to 10 g/L
- How to optimize manufacturability with assured gene integration and robust and stable clones
- Q&A session with our expert
Why SynWeave™
SynWeave™ leverages state-of-the-art cell line and transposon-based technologies from ExcellGene, seamlessly integrated with Syngene’s advanced process development capabilities. This synergy dramatically enhances manufacturability and efficiency, ensuring faster and more reliable protein production.Key Advantages:
- Accelerated Development: Save up to 10 weeks compared to traditional methods, streamlining your process.
- Increased Productivity: Achieve high titer levels of up to 10 g/L with optimized processes.
- Versatile Application: Supports a wide range of products including mAbs, biosimilars, bispecifics, ADCs, and other recombinant proteins
Speaker Bio
Sunit Maity, PhD
Dr. Sunit was trained as developmental/cardiovascular Biologists in Leuven, Belgium where he received his PhD. He worked in industry (Mermaid Pharmaceuticals, Hamburg Germany) for three years where he was involved in target identification using model system. He has spent time at Max Planck Institute, Germany where he was involved in the CNS development related project. After coming back to India in 2007, he joined Avesthagen where he headed the biosimilar group at the end. He was responsible for development of biologics including recombinant protein and monoclonal antibodies using mammalian expression system. Thereafter, he was associated with Zumutor Biologics since its inception and worked as Director of Product Development team. His team’s role at Zumutor was focused on developing process and scale-up for novel monoclonal antibody drug in the ImmuneOncology segment. Currently, he is working as Sr General Manager, Biopharmaceutical development at Syngene.
